All In Biotech

Drug Trial Radar · NCT07290985

AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas

AACR Adaptive Biomarker-Driven Organ Preservation Trial In Gastroesophageal Adenocarcinomas (AACR-ADOPT-GEA)

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

242

Planned (sponsor's estimate)

Start

Jul 20, 2026

Primary completion

Jun 1, 2028

Study completion Dec 1, 2028

Sponsor

Lead sponsor
American Association for Cancer ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jazz Pharmaceuticals; BeOne Medicines; Astellas Pharma Inc; Natera, Inc.; Roche Diagnostics GmbH
First posted
Dec 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test a new personalized treatment approach for patients with stomach or esophageal cancer. It will take place in two stages and aims to find the best combination of chemotherapy, immunotherapy, and targeted drugs based on each patient's tumor biomarkers. Upon enrollment onto the study, patients will consent to tumor biomarker testing and may receive one cycle of standard chemotherapy while awaiting results. Those with a matching biomarker will join the corresponding treatment group that combines chemotherapy, an immune checkpoint inhibitor, and/or a targeted therapy. In Stage I of the study, treatment lasts about four months before surgery, followed by an additional eight months of therapy for a total of one year. The most effective treatments from Stage I will be studied further in Stage II of the study to see whether some patients can safely avoid surgery. Those patients enrolled during Stage II will receive four months of the same combination treatment (chemotherapy, an immune checkpoint inhibitor, and/or a targeted therapy) but may be eligible to skip surgery if their cancer completely disappears after pre-surgery therapy. All patients will then receive an additional eight months of therapy and those who skipped surgery will be closely monitored with scans and endoscopies.

Conditions

  • Gastroesophageal Adenocarcinoma

Interventions

  • TislelizumabDrug

    150 mg every 2 weeks for 4 months pre-operatively and up to 8 months post-operatively

  • LeucovorinDrug

    400 mg/m² every 2 weeks for 4 months pre-operatively

  • OxaliplatinDrug

    85 mg/m² every 2 weeks for 4 months pre-operatively

  • FluorouracilDrug

    2,400 mg/m² every 2 weeks for 4 months pre-operatively

  • ZanidatamabDrug

    1,200 mg for patients weighing less than 70 kg and 1,600 mg for patients weighing 70 kg or more every 2 weeks for 4 months pre-operatively and up to 8 months post-operatively

  • ZolbetuximabDrug

    A loading dose of 800mg/m2 zolbetuximab will be administered at cycle 1, followed by subsequent doses of 400 mg/m2 every 2 weeks for 4 months pre-operatively and up to 8 months post-operatively. In the postoperative maintenance therapy phase, dosing of 600 mg/m2 every 3 weeks may also be used

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological Complete Response (pathCR) Rate (Stage I).Time frame: At time of surgery.
  2. Organ Preservation Rate (Stage II)Time frame: Up to 12 months post-treatment.

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.